Cellicure develops patented CAR-NK and CAR-T technologies that enhance the activation and persistence of natural killer and T cells for immunotherapy. The company addresses the unmet clinical needs of patients with solid tumors and hematological malignancies by providing effective cell-based treatments for cancer and chronic inflammatory diseases.
Funding
$5.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell-based cancer immunotherapies face challenges in effectively targeting and eradicating solid tumors and hematological malignancies due to limitations in cell activation, persistence, and scalability. Traditional methods of natural killer (NK) cell expansion and T-cell engineering often require continuous cytokine stimulation and lack the ability to overcome inhibitory signaling barriers, hindering their therapeutic potential.
Solution
Cellicure develops and patents CAR-NK and CAR-T cell technologies designed to enhance the activation and persistence of immune cells for improved cancer immunotherapy. Their complete signaling CAR (csCAR-NK) technology overcomes inhibitory signaling in NK cells, leading to complete activation. The cytokine-free renewable NK (reNKTM) platform enables long-term NK cell renewability without continuous cytokine stimulation. Cellicure's NK expansion system (Effic-NKTM) simplifies the NK cell expansion process, increasing efficiency and reducing costs. The nCAR-TTM platform enhances the persistence of CAR-T cells, improving their immunotherapy efficacy.
Target Audience
Cellicure's primary target audience includes researchers and clinicians in the fields of oncology and immunology, as well as pharmaceutical companies developing cell-based immunotherapies for cancer and chronic inflammatory diseases.
Features
- csCAR-NK: Complete signaling CAR technology that enhances NK cell activation by overcoming inhibitory signals.
- reNKTM: Cytokine-free renewable NK cell platform enabling long-term NK cell expansion without continuous cytokine stimulation.
- Effic-NKTM: NK cell expansion system that simplifies the expansion process, improving efficiency and reducing costs.
- nCAR-TTM: CAR-T cell platform that enhances CAR-T cell persistence for improved immunotherapy efficacy.